Navigation Links
Cytokinetics Reports Additional Clinical Trials Data for Ispinesib

all of these trials; patients remain on treatment in the renal cell cancer trial. Data from the other trials have already been reported.

The NCI has completed patient treatment in a Phase I clinical trial designed to evaluate the safety, tolerability and pharmacokinetics of ispinesib on an alternative dosing schedule in patients with advanced solid tumors that have failed to respond to all standard therapies; data from this trial have already been reported. The NCI is continuing patient enrollment in a Phase I clinical trial designed to evaluate the safety, tolerability and pharmacokinetics of ispinesib on an alternative dosing schedule in patients with relapsed or refractory acute leukemia, chronic myelogenous leukemia in blast crisis, or advanced myelodysplastic syndromes. Data from this trial are expected in 2007.

Background on Mitotic Kinesin Inhibitors

Since their introduction over 40 years ago, anti-mitotic drugs (taxanes and vinca alkaloids) have advanced the treatment of cancer and are commonly used for the treatment of several tumor types. However, these drugs have demonstrated limited treatment benefit against certain cancers. In addition, these drugs target tubulin, a cytoskeletal protein involved not only in mitosis and cell proliferation, but also in other important cellular functions. Inhibition of these other cellular functions produces dose-limiting toxicities such as peripheral neuropathy, an impairment of peripheral nervous system function. Neuropathies are thought to result when these drugs interfere with the dynamics of microtubule filaments that are responsible for the long-distance transport of important cellular components within nerve cells.

Mitotic kinesins are essential to mitosis, and, unlike tubulin, appear to have no role in other cellular functions. Cytokinetics believes that drugs that inhibit KSP and CENP-E and other mitotic kinesins may represent the next generation of anti-mitotic cancer drugs
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Cytokinetics Announces Non-clinical Data to be Presented at the 2007 AACR Annual Meeting
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
(Date:7/24/2014)... , July 24, 2014   AcelRx Pharmaceuticals, Inc. ... focused on the development and commercialization of innovative therapies ... confirmed the PDUFA date for Zalviso remains July 27, ... rumor circulated online stating the Food and Drug Administration ... there has been no notification to the company from ...
(Date:7/24/2014)... , July 24, 2014  Restore Health, ... and compounded pharmaceuticals, announced that it is now ... unique to each individual based upon their particular ... by understanding the interaction between a patient,s genetics ... "We,re very excited to provide this new service ...
(Date:7/24/2014)... 24, 2014  Uroplasty, Inc. (NASDAQ: UPI ... and markets innovative proprietary products to treat voiding ... 2015 first quarter ended June 30, 2014.  ... Neuromodulation System grew 19% to $4.1 million, as ... of the prior year.  Total revenue for the ...
Breaking Medicine Technology:AcelRx Pharmaceuticals Confirms July 27, 2014 PDUFA Date for Zalviso 2Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 2Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 3Uroplasty Reports Fiscal First Quarter Results 2Uroplasty Reports Fiscal First Quarter Results 3Uroplasty Reports Fiscal First Quarter Results 4Uroplasty Reports Fiscal First Quarter Results 5Uroplasty Reports Fiscal First Quarter Results 6Uroplasty Reports Fiscal First Quarter Results 7Uroplasty Reports Fiscal First Quarter Results 8Uroplasty Reports Fiscal First Quarter Results 9Uroplasty Reports Fiscal First Quarter Results 10Uroplasty Reports Fiscal First Quarter Results 11
... Feb. 24, 2011 Reportlinker.com announces that a ... catalogue: Global Computer Assisted ... http://www.reportlinker.com/p0397748/Global-Computer-Assisted-Surgical-CAS-Systems-Industry.html This report analyzes ... Systems in US$ Million by the following Product ...
... Reportlinker.com announces that a new market research report is ... Drug-Eluting Stents Industry http://www.reportlinker.com/p080457/Global-Drug-Eluting-Stents-Industry.html ... for Drug-Eluting Stents in US$ Million. The report provides ... Rest of World. Annual estimates and forecasts are provided ...
Cached Medicine Technology:Reportlinker Adds Global Computer Assisted Surgical (CAS) Systems Industry 2Reportlinker Adds Global Drug-Eluting Stents Industry 2
(Date:7/25/2014)... The North America Artificial lift market report ... with analysis and forecast of revenue. The artificial lift market ... billion in 2013 to around $7 billion by 2018, at ... Browse through the TOC of North America artificial lift market ... also provides a glimpse of the segmentation in North America ...
(Date:7/25/2014)... Agoura Hills dentist , Dr. Amir ... Zoom Whitening is one of the most powerful whitening treatments ... professional. This light-assisted treatment uses a prescription-strength gel that can ... to break up stains that are in both the enamel ... soft drink and tobacco stains. , About Dr. Amir ...
(Date:7/25/2014)... July 25, 2014 The rising pharmaceutical sale ... to the growth of the US PBM industry. A slow ... value of pharmaceutical sales in the US over the past ... attributed to rise in the prescription volume over the past ... Benefit Management (PBM): 2013 Edition” the demand for the pharmacy ...
(Date:7/25/2014)... 25, 2014 Ross A. Clevens, MD, ... invited to join the exclusive Obagi Clinical Advisory Board, ... plastic surgeons, plastic surgeons and dermatologists. , Dr. ... Advisory Board of thought leaders held its first meeting ... was to give Obagi the opportunity to meet with ...
(Date:7/25/2014)... FRIDAY, July 25, 2014 (HealthDay News) -- Dietary changes ... gut on a daily basis, according to a new ... systems that might help detect and ease flare-ups for ... disease (ulcerative colitis and Crohn,s disease), the researchers said. ... but their effect on human health isn,t well understood, ...
Breaking Medicine News(10 mins):Health News:North America Artificial Lift Services Market is Expected to Reach $7 Billion in 2018 - New Report by MicroMarket Monitor 2Health News:North America Artificial Lift Services Market is Expected to Reach $7 Billion in 2018 - New Report by MicroMarket Monitor 3Health News:North America Artificial Lift Services Market is Expected to Reach $7 Billion in 2018 - New Report by MicroMarket Monitor 4Health News:Agoura Hills Dentist, Dr. Amir Choroomi, is Now Offering a Promotion on Zoom Whitening 2Health News:US Pharmacy Benefit Management (PBM) Market Trends and Developments Now Available at MarketReportsOnline.com 2Health News:US Pharmacy Benefit Management (PBM) Market Trends and Developments Now Available at MarketReportsOnline.com 3Health News:Renowned Melbourne Plastic Surgeon to Join Private Medical Advisory Board 2Health News:Diet Changes Can Alter Gut Bacteria, Study Says 2
... 10 The Community Oncology Alliance (COA) today issued a ... their practices if critical Medicare reimbursement fixes for treating cancer ... reform. , "Current health reform legislation before Congress does not ... in January to cancer care," said Patrick Cobb, ...
... , SACRAMENTO, Calif., Dec. 10 ... California Affiliates of Susan G. Komen for the Cure® signaled ... Every Woman Counts program, which would effectively shut ... low-income and uninsured women for the first six months of ...
... A never-approved drug developed to prevent the death of nerve ... keeping normal cells healthy and intact, an international team led ... journal Breast Cancer Research . Prof. Malka ... stroke drug a member of a family of phenanthridine ...
... ... Laser-type device to be ... San Diego (PRWEB) ... jointly entered into a letter of intent with Advanced Light Devices to develop a proprietary laser system. It ...
... , SILVER SPRING, Md., Dec. 10 The U.S. ... approved to replace a portion of plasma used when storing ... donor plasma to be used for other purposes. , (Logo: ... platelets, which are blood components that help with blood clotting, ...
... SALEM, Ore., Dec. 10 West Coast Bank,s Salem Battle Creek ... hospitalized at the Salem Hospital Pediatric Wing and Neonatal Intensive Care ... branch, 5686 Commercial St. SE, Suite 110 on week days from ... Manager of Pediatrics at Salem Hospital said, "The hospital is in ...
Cached Medicine News:Health News:National Oncologist Group Warns: Current Health Care Reform Legislation Woefully Short in Addressing Cancer Care Crisis 2Health News:National Oncologist Group Warns: Current Health Care Reform Legislation Woefully Short in Addressing Cancer Care Crisis 3Health News:National Oncologist Group Warns: Current Health Care Reform Legislation Woefully Short in Addressing Cancer Care Crisis 4Health News:California Breast Cancer Survivors and Advocates Call on State to Nix Screening Cuts 2Health News:California Breast Cancer Survivors and Advocates Call on State to Nix Screening Cuts 3Health News:Finding the Achilles' heel of cancer 2Health News:Entest BioMedical Enters into LOI with Advanced Light Devices to Develop Laser Platform for Stem Cell / Laser COPD Treatment 2Health News:Entest BioMedical Enters into LOI with Advanced Light Devices to Develop Laser Platform for Stem Cell / Laser COPD Treatment 3Health News:FDA Approves First Additive Solution for Platelet Storage Up to 5 Days 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: